Sino Biological - Custom Protein Production Services
Pharma Focus America
Get published
Revvity Signals || Signals One™
magazine-slider-image
Get Latest e-Book

EDITORIAL SECTION

Advisory Board

Victor M. Diaz Perez

Victor M. Diaz Perez
Kishore Hotha

Kishore Hotha
Joab Williamson

Joab Williamson
Scott M. Wheelwright

Scott M. Wheelwright
Tamara Miller

Tamara Miller
Juris Hmelnickis

Juris Hmelnickis
David Contorno

David Contorno
Svetlana Busiguina

Svetlana Busiguina
Eiman Shafa

Eiman Shafa
Nigel Cryer FRSC

Nigel Cryer FRSC

 .
Hector Alejandro Andonie

Hector Alejandro Andonie

 .
Josipa Ljubicic

Josipa Ljubicic

 .

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

press releasesRead more...

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Fortrea a leading global contract research organization CRO and Omico Australias leading precision oncology screening and trial matching organization today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarkermatched clinical trials By co...

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

Charles River Laboratories International Inc announced a Research Collaboration Agreement RCA with the US Food and Drug Administration FDA and Labcorp for developing sensitive screening tools to quantify and rank the abuse potential of new drugs including abusedeterrent formulations

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

BioCryst Pharmaceuticals Inc announced the US Food and Drug Administration FDA has approved its supplemental New Drug Application sNDA for use of the oral pellet formulation of oncedaily ORLADEYO berotralstat for prophylactic therapy in adults and adolescents aged years and older

Radical Numerics Launches Omnii-1, a New Generation of Biological AI, as First AI-Designed Phage Therapy Reaches Human Patient

Radical Numerics an AI research lab building general biological intelligence today launched Omnii a biological AI model that learns across DNA RNA proteins and other molecular data Researchers used Omnii to design a bacteriophage and administered it to a patient with a drugresistant bacterial infect...

Events Read more...

21 - 23

Oct 2026

Drug Formulation & Drug Delivery 2026

Paris, France

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

BIOPLUS-INTERPHEX Korea

COEX, Seoul

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

02 - 04

Nov 2026

Cancer R&D 2026

Houston, TX, USA

LATEST NEWSRead more...

Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center

Ignite Proteomics Inc a precision oncology company focused on functional proteomics today announced it is collaborating with Memorial Sloan Kettering Cancer Center MSK to study protein signaling patterns associated with treatment response and resistance in advanced breast cancer

Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research

Warp Sciences today emerged from stealth with million in funding to create the infrastructure that enables biotech and pharmaceutical companies to discover new medicines faster The company is building a USbased chemistry contract research organization CRO that brings expert chemists

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

Merck known as MSD outside of the United States and Canada today announced the European Commission EC has approved KEYTRUDA pembrolizumab Mercks antiPD therapy in combination with Padcev enfortumab vedotinejfv as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment...

Verily Health and Autoimmune Registry Partner to Build Cross-Disease Research Infrastructure for Autoimmune Conditions

Verily Health Inc a healthcare data intelligence company today announced a strategic partnership with Autoimmune Registry Inc ARI a nonprofit nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J Fox for its work studying autoimmune diseases the populations they affect a...

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc announced the US Food and Drug Administration FDA has approved Jemperli dostarlimab as the first and only immunotherapy for adults with stage II and III microsatellite instabilityhigh MSIHmismatch repair deficient dMMR locally advanced rectal cancer under the accelerated approval pathway

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Alcon the global leader in eye care dedicated to helping people see brilliantly today announced it has acquired Neurotech Pharmaceuticals Inc a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases

Sartorius || Claim your complimentary Cytokines
Infors HT - Multifors 3
ICON: Manufacturing & Pharmacy Services
Yokogawa || Why Data Integrity Has Become a Boardroom Issue
Bend Bioscience - The Development-GMP Gap